Treatment of multiple sclerosis with intravenous immunoglobulin: Review of clinical trials

Neurological Sciences

Volumn 24, Issue SUPPL. 4, 2003, Pages

  Sorensen P S ^a  

^a Mental Health Services CPH   (Denmark)

Author keywords

Clinical trials; Immunoglobulin G; Intravenous immunoglobulin; Multiple sclerosis; Theraphy

Indexed keywords

BETA INTERFERON; GLATIRAMER; IMMUNOGLOBULIN; PLACEBO;

ADULT; CLINICAL TRIAL; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HAND ECZEMA; HEPATITIS C; HUMAN; LUNG EMBOLISM; MACROPHAGE MIGRATION INHIBITION; META ANALYSIS; MOTOR DYSFUNCTION; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOMES RESEARCH; RECURRENCE RISK; REMISSION; REMYELINIZATION; REVIEW; SYMPTOMATOLOGY; VISUAL ACUITY; VISUAL DISORDER;

CLINICAL TRIALS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 0142248467     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10072-003-0083-5     Document Type: Review

References (20)

1. Hafler DA, Brod SA, Weiner HL (1989) Immunoregulation in multiple sclerosis. Res Immunol 140:233-239
2. Storch M, Lassmann H (1997) Pathology and pathogenesis of demyelinating diseases. Curr Opin Neurol 10:186-192
3. Dalakas MC (1998) Mechanism of action of intravenous immunoglobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases. Neurology 51[Suppl 5]:S2-S8
4. Kazatchkine MD, Kaveri SV (2001) Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345:747-755
5. Sorensen PS (1994) Treatment of multiple sclerosis with IVIg: potential effects and methodology of clinical trials. J Neurol Neurosurg Psychiatry 57[Suppl]:62-64
6. Sørensen PS (1996) Intravenous immunoglobulin G therapy: effects of acute and chronic treatment in multiple sclerosis. Mult Scler 1:349-352
7. Fazekas F, Deisenhammer F, Strasser Fuchs S, Nahler G, Mamoli B (1997) Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet 349:589-593
8. Achiron A, Gabbay U, Gilad R, Hassin BS, Barak Y, Gornish M et al (1998) Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology 50:398-402
9. Sorensen PS, Wanscher B, Jensen CV, Schreiber K, Blinkenberg M, Ravnborg M et al (1998) Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 50:1273-1281
10. Lewanska M, Siger-Zajdel M, Selmaj K (2002). No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment. Eur J Neurol 9:565-572
11. Sørensen PS, Fazekas F, Lee M (2002) Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis. Eur J Neurol 9:557-563
12. Noseworthy JH, O'Brien PC, Petterson TM, Weis J, Stevens L, Peterson WK et al (2001) A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology 56:1514-1522
13. Noseworthy JH, O'Brien PC, Weinshenker BG, Weis JA, Petterson TM, Erickson BJ et al (2000) IV immunoglobulin does not reverse established weakness in MS. Neurology 55:1135-1143
14. Stangel M, Boegner F, Klatt CH, Hofmeister C, Seyfert S (2000) Placebo controlled pilot trial to study the remyelinating potential of intravenous immunoglobulins in multiple sclerosis. J Neurol Neurosurg Psychiatry 68:89-92
15. Sørensen PS (2003) The role of intravenous immunoglobulin in the treatment of multiple sclerosis. J Neurol Sci 206:123-130
16. The IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:655-661
17. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM et al (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39:285-294
18. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352:1498-1504
19. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP et al (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45:1268-1276
20. Comi G, Filippi M, Wolinsky JS (2001). European/Canadian multicenter, double-blind, randomized, placebo- controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 49:290-297